{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T16:34:26Z","timestamp":1793378066594,"version":"4.5.0"},"reference-count":217,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2012,11,1]],"date-time":"2012-11-01T00:00:00Z","timestamp":1351728000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Supportive Oncology"],"published-print":{"date-parts":[[2012,11]]},"DOI":"10.1016\/j.suponc.2012.05.002","type":"journal-article","created":{"date-parts":[[2012,7,17]],"date-time":"2012-07-17T15:36:11Z","timestamp":1342539371000},"page":"209-219","source":"Crossref","is-referenced-by-count":165,"title":["Twelve Reasons for Considering Buprenorphine as a Frontline Analgesic in the Management of Pain"],"prefix":"10.1016","volume":"10","author":[{"given":"Mellar P.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib1","doi-asserted-by":"crossref","first-page":"395","DOI":"10.2174\/1570159043359477","article-title":"Buprenorphine: a unique drug with complex pharmacology","volume":"2","author":"Lutfy","year":"2004","journal-title":"Curr Neuropharmacol"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib2","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/j.1533-2500.2010.00378.x","article-title":"Current knowledge of buprenorphine and its unique pharmacological profile","volume":"10","author":"Pergolizzi","year":"2010","journal-title":"Pain Pract"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib3","doi-asserted-by":"crossref","first-page":"421","DOI":"10.2147\/CIA.S1880","article-title":"Management of chronic pain in the elderly: focus on transdermal buprenorphine","volume":"3","author":"Vadivelu","year":"2008","journal-title":"Clin Interv Aging"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib4","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1093\/bja\/aeg133","article-title":"Old dog\u2013new (ma)trix","volume":"90","author":"Budd","year":"2003","journal-title":"Br J Anaesth"},{"issue":"133","key":"10.1016\/j.suponc.2012.05.002_bib5","first-page":"9","article-title":"Buprenorphine and the transdermal system: the ideal match in pain management","author":"Budd","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1533-2500.2007.00119.x","article-title":"Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients","volume":"7","author":"Freye","year":"2007","journal-title":"Pain Pract"},{"issue":"7","key":"10.1016\/j.suponc.2012.05.002_bib7","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1016\/j.clinthera.2005.06.024","article-title":"Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study","volume":"27","author":"Sittl","year":"2005","journal-title":"Clin Ther"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib8","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s00520-008-0546-6","article-title":"Equipotent doses to switch from high doses of opioids to transdermal buprenorphine","volume":"17","author":"Mercadante","year":"2009","journal-title":"Support Care Cancer"},{"issue":"1-3","key":"10.1016\/j.suponc.2012.05.002_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2004.11.052","article-title":"Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain","volume":"507","author":"Christoph","year":"2005","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib10","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ejpain.2008.04.011","article-title":"Clinical update on the pharmacology, efficacy and safety of transdermal buprenorphine","volume":"13","author":"Kress","year":"2009","journal-title":"Eur J Pain"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib11","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(91)90485-9","article-title":"Buprenorphine and morphine cause antinociception by different transduction mechanisms","volume":"195","author":"Wheeler-Aceto","year":"1991","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib12","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1111\/j.1476-5381.1995.tb13346.x","article-title":"Subgroups among mu-opioid receptor agonists distinguished by ATP-sensitive K+ channel-acting drugs","volume":"114","author":"Oca\u00f1a","year":"1995","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib13","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0361-9230(00)00448-2","article-title":"Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia","volume":"54","author":"S\u00e1nchez-Bl\u00e1zquez","year":"2001","journal-title":"Brain Res Bull"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib14","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/sj.bjp.0706661","article-title":"Differential activation of G-proteins by mu-opioid receptor agonists","volume":"147","author":"Saidak","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"11","key":"10.1016\/j.suponc.2012.05.002_bib15","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1007\/s11064-011-0525-z","article-title":"Differential pharmacological actions of methadone and buprenorphine in human embryonic kidney 293 cells coexpressing human mu-opioid and opioid receptor-like 1 receptors","volume":"36","author":"Lee","year":"2011","journal-title":"Neurochem Res"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1533-2500.2008.00204.x","volume":"8","author":"Pergolizzi","year":"2008","journal-title":"Pain Pract"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib17","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0022-3565(24)35398-4","article-title":"Ligand-induced changes in surface mu-opioid receptor number: relationship to G protein activation?","volume":"292","author":"Zaki","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib18","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1476-5381.1977.tb07533.x","article-title":"The animal pharmacology of buprenorphine, an oripavine analgesic agent","volume":"60","author":"Cowan","year":"1977","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib19","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0022-3565(25)23126-3","article-title":"Behavioral and neurochemical interactions between cocaine and buprenorphine: implications for the pharmacotherapy of cocaine abuse","volume":"256","author":"Brown","year":"1991","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.suponc.2012.05.002_bib20","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/S0196-9781(00)00245-X","article-title":"Nociceptin\/orphanin FQ and drugs of abuse","volume":"21","author":"Ciccocioppo","year":"2000","journal-title":"Peptides"},{"issue":"1-2","key":"10.1016\/j.suponc.2012.05.002_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S0014-2999(00)00590-2","article-title":"Effect of nociceptin\/orphanin FQ on the rewarding properties of morphine","volume":"404","author":"Ciccocioppo","year":"2000","journal-title":"Eur J Pharmacol"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib22","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1093\/jat\/20.6.369","article-title":"Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine","volume":"20","author":"Kuhlman","year":"1996","journal-title":"J Anal Toxicol"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib23","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/00912709922008236","article-title":"Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations","volume":"39","author":"Nath","year":"1999","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib24","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1177\/009127009703700106","article-title":"Bioavailability of sublingual buprenorphine","volume":"37","author":"Mendelson","year":"1997","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib25","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1038\/clpt.1980.219","article-title":"Buprenorphine kinetics","volume":"28","author":"Bullingham","year":"1980","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib26","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3109\/00498258109045291","article-title":"Biliary excretion, metabolism and enterohepatic circulation of buprenorphine","volume":"11","author":"Brewster","year":"1981","journal-title":"Xenobiotica"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2165\/00003495-197917020-00001","article-title":"Buprenorphine: a review of its pharmacological properties and therapeutic efficacy","volume":"17","author":"Heel","year":"1979","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib28","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1124\/dmd.31.6.768","article-title":"Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro","volume":"31","author":"Zhang","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib29","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1248\/bpb.25.682","article-title":"Inhibition of human drug metabolizing cytochrome P450 by buprenorphine","volume":"25","author":"Umehara","year":"2002","journal-title":"Biol Pharm Bull"},{"issue":"7","key":"10.1016\/j.suponc.2012.05.002_bib30","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0009-9120(02)00304-1","article-title":"A new series of 13 buprenorphine-related deaths","volume":"35","author":"Kintz","year":"2002","journal-title":"Clin Biochem"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib31","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpainsymman.2004.07.005","article-title":"Buprenorphine: considerations for pain management","volume":"29","author":"Johnson","year":"2005","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib32","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S0090-9556(25)07765-7","article-title":"The metabolism and excretion of buprenorphine in humans","volume":"12","author":"Cone","year":"1984","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1353-1131(03)00039-7","article-title":"Tramadol-benzodiazepines and buprenorphine-benzodiazepines: two potentially fatal cocktails?","volume":"10","author":"Clarot","year":"2003","journal-title":"J Clin Forensic Med"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib34","doi-asserted-by":"crossref","first-page":"17","DOI":"10.2165\/00003088-199937010-00002","article-title":"Pharmacokinetics of opioids in liver disease","volume":"37","author":"Tegeder","year":"1999","journal-title":"Clin Pharmacokinet"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib35","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1097\/ALN.0b013e318238fea0","article-title":"Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active","volume":"115","author":"Brown","year":"2011","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib36","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/toxsci\/65.1.107","article-title":"Buprenorphine and midazolam act in combination to depress respiration in rats","volume":"65","author":"Gueye","year":"2002","journal-title":"Toxicol Sci"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib37","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/sj.clpt.6100025","article-title":"Mechanism-based PK\/PD modeling of the respiratory depressant effect of buprenorphine and fentanyl in healthy volunteers","volume":"81","author":"Yassen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib38","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0022-3565(24)36604-2","article-title":"Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine","volume":"281","author":"Ohtani","year":"1997","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib39","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1185\/03007990902920731","article-title":"The role of transdermal buprenorphine in the treatment of cancer pain: an expert panel consensus","volume":"25","author":"Pergolizzi","year":"2009","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib40","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jpainsymman.2009.09.009","article-title":"Errors in opioid prescribing: a prospective survey in cancer pain","volume":"39","author":"Shaheen","year":"2010","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib41","first-page":"511","article-title":"Opioid rotation in cancer patients: pros and cons","volume":"19","author":"Estfan","year":"2005","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.suponc.2012.05.002_bib42","doi-asserted-by":"crossref","first-page":"c4462","DOI":"10.1136\/bmj.c4462","article-title":"Opioid induced hypogonadism","volume":"341","author":"Reddy","year":"2010","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.suponc.2012.05.002_bib43","doi-asserted-by":"crossref","first-page":"825","DOI":"10.2165\/00003088-200746100-00002","article-title":"Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics","volume":"46","author":"Davis","year":"2007","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib44","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.jpainsymman.2004.02.021","article-title":"Opioids in renal failure and dialysis patients","volume":"28","author":"Dean","year":"2004","journal-title":"J Pain Symptom Manage"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib45","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/SPC.0b013e3283437a39","article-title":"Transdermal opioids for cancer pain","volume":"5","author":"Cachia","year":"2011","journal-title":"Curr Opin Support Palliat Care"},{"issue":"10","key":"10.1016\/j.suponc.2012.05.002_bib46","first-page":"380","article-title":"Erroneous downstream occlusion alarms may disable Smiths Medical CADD-Solis infusion pumps","volume":"39","year":"2010","journal-title":"Health Devices"},{"issue":"9-10","key":"10.1016\/j.suponc.2012.05.002_bib47","first-page":"360","article-title":"Patient-controlled analgesic infusion pumps","volume":"30","year":"2001","journal-title":"Health Devices"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib48","first-page":"84","article-title":"Improper cassette attachment allows gravity free-flow from SIMS-Deltec CADD-series pumps","volume":"24","year":"1995","journal-title":"Health Devices"},{"issue":"11","key":"10.1016\/j.suponc.2012.05.002_bib49","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1007\/s00520-005-0849-9","article-title":"Buprenorphine in cancer pain","volume":"13","author":"Davis","year":"2005","journal-title":"Support Care Cancer"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib50","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1734-1140(11)70609-0","article-title":"Transdermal buprenorphine in the treatment of cancer and non-cancer pain\u2014the results of multicenter studies in Poland","volume":"63","author":"Przeklasa-Muszy\u0144ska","year":"2011","journal-title":"Pharmacol Rep"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib51","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1185\/03007995.2011.569017","article-title":"Transdermal buprenorphine for the treatment of moderate to severe chronic pain: results from a large multicenter, non-interventional post-marketing study in Poland","volume":"27","author":"Przeklasa- Muszy\u0144ska","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib52","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1213\/01.ANE.0000145066.06538.20","article-title":"Transdermal buprenorphine for treating nociceptive and neuropathic pain: four case studies","volume":"100","author":"Likar","year":"2005","journal-title":"Anesth Analg"},{"issue":"8","key":"10.1016\/j.suponc.2012.05.002_bib53","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1185\/030079905X53315","article-title":"Transdermal buprenorphine in clinical practice\u2014a post-marketing surveillance study in 13,179 patients","volume":"21","author":"Griessinger","year":"2005","journal-title":"Curr Med Res Opin"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2012.05.002_bib54","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1191\/0269216306pm1125oa","article-title":"Transdermal buprenorphine in cancer pain and palliative care","volume":"20","author":"Sittl","year":"2006","journal-title":"Palliat Med"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib55","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.clinthera.2005.04.007","article-title":"Effectiveness and tolerability of the buprenorphine transdermal system in patients with moderate to severe chronic pain: a multicenter, open-label, uncontrolled, prospective, observational clinical study","volume":"27","author":"Muriel","year":"2005","journal-title":"Clin Ther"},{"issue":"4-5","key":"10.1016\/j.suponc.2012.05.002_bib56","first-page":"109","article-title":"Oral tramadol and buprenorphine in tumour pain","volume":"16","author":"Brema","year":"1996","journal-title":"Int J Clin Pharmacol Res"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib57","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00002508-198906000-00004","article-title":"Continuous subcutaneous infusion of buprenorphine for cancer pain control","volume":"5","author":"Noda","year":"1989","journal-title":"Clin J Pain"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib58","first-page":"587","article-title":"Chronic analgesic study on buprenorphine action in cancer pain","volume":"33","author":"Ventafridda","year":"1983","journal-title":"Arzneimittelforschung"},{"issue":"suppl 3","key":"10.1016\/j.suponc.2012.05.002_bib59","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1111\/j.1365-2125.1979.tb04706.x","article-title":"A trial of sublingual buprenorphine in cancer pain","volume":"7","author":"Robbie","year":"1979","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"10.1016\/j.suponc.2012.05.002_bib60","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1016\/j.clinthera.2009.10.013","article-title":"Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: a 4-week, nonrandomized, open-label, uncontrolled observational study","volume":"31","author":"Mercadante","year":"2009","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib61","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1185\/03007995.2012.678938","article-title":"Systematic review of efficacy and safety of buprenorphine versus fentanyl or morphine in patients with chronic moderate to severe pain","volume":"28","author":"Wolff","year":"2012","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib62","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1152\/jn.1991.66.1.190","article-title":"Neurogenic hyperalgesia: psychophysical studies of underlying mechanisms","volume":"66","author":"LaMotte","year":"1991","journal-title":"J Neurophysiol"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib63","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jpainsymman.2010.10.268","article-title":"Pronociceptive pain modulation in patients with painful chemotherapy-induced polyneuropathy","volume":"42","author":"Nahman-Averbuch","year":"2011","journal-title":"J Pain Symptom Manage"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib64","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1152\/jn.1997.78.6.3351","article-title":"Circuitry underlying antiopioid actions of orphanin FQ in the rostral ventromedial medulla","volume":"78","author":"Heinricher","year":"1997","journal-title":"J Neurophysiol"},{"issue":"1-2","key":"10.1016\/j.suponc.2012.05.002_bib65","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.pain.2005.06.030","article-title":"Different profiles of buprenorphine-induced analgesia and antihyperalgesia in a human pain model","volume":"118","author":"Koppert","year":"2005","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib66","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0014-2999(02)02052-6","article-title":"Buprenorphine alleviates neuropathic pain-like behaviors in rats after spinal cord and peripheral nerve injury","volume":"450","author":"Kouya","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib67","doi-asserted-by":"crossref","first-page":"195","DOI":"10.5055\/jom.2007.0005","article-title":"Buprenorphine\u2014a review of its role in neuropathic pain","volume":"3","author":"Hans","year":"2007","journal-title":"J Opioid Manag"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib68","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1097\/00000542-200108000-00022","article-title":"A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine","volume":"95","author":"Koppert","year":"2001","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib69","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/00000542-200002000-00029","article-title":"Long-lasting hyperalgesia induced by fentanyl in rats: preventive effect of ketamine","volume":"92","author":"C\u00e9l\u00e8rier","year":"2000","journal-title":"Anesthesiology"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib70","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0022-3565(25)20032-5","article-title":"Intracerebroventricular morphine decreases descending inhibitions acting on lumbar dorsal horn neuronal activities related to pain in the rat","volume":"247","author":"Bouhassira","year":"1988","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib71","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0304-3959(92)90126-V","article-title":"Morphine blocks descending pain inhibitory controls in humans","volume":"48","author":"Le Bars","year":"1992","journal-title":"Pain"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2012.05.002_bib72","doi-asserted-by":"crossref","first-page":"S549","DOI":"10.1016\/0024-3205(83)90562-3","article-title":"Morphine microinjections into periaqueductal grey matter of the rat: effects on dorsal horn neuronal responses to C-fibre activity and diffuse noxious inhibitory controls","volume":"33","author":"Dickenson","year":"1983","journal-title":"Life Sci"},{"issue":"1-2","key":"10.1016\/j.suponc.2012.05.002_bib73","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0006-8993(81)90506-0","article-title":"The effect of systemic morphine upon diffuse noxious inhibitory controls (DNIC) in the rat: evidence for a lifting of certain descending inhibitory controls of dorsal horn convergent neurones","volume":"215","author":"Le Bars","year":"1981","journal-title":"Brain Res"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib74","first-page":"55","article-title":"Diffuse noxious inhibitory controls (DNIC) in animals and in man","author":"Le Bars","year":"1992","journal-title":"Patol Fiziol Eksp Ter"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib75","first-page":"187","article-title":"Implications of intrathecal pertussis toxin animal model on the cellular mechanisms of neuropathic pain syndrome","volume":"41","author":"Wen","year":"2003","journal-title":"Acta Anaesthesiol Sin"},{"issue":"2-3","key":"10.1016\/j.suponc.2012.05.002_bib76","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S0304-3959(97)03329-0","article-title":"Intrathecal pertussis toxin produces hyperalgesia and allodynia in mice","volume":"70","author":"Womer","year":"1997","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib77","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/S0304-3959(98)00146-8","article-title":"Some new insights into the effects of opioids in phasic and tonic nociceptive tests","volume":"78","author":"McCormack","year":"1998","journal-title":"Pain"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib78","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1533-2500.2010.00434.x","article-title":"Transdermal buprenorphine for central neuropathic pain: clinical reports","volume":"11","author":"Guetti","year":"2011","journal-title":"Pain Pract"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib79","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1049909109341868","article-title":"Buprenorphine for neuropathic pain\u2014targeting hyperalgesia","volume":"26","author":"Induru","year":"2009","journal-title":"Am J Hosp Palliat Care"},{"issue":"10","key":"10.1016\/j.suponc.2012.05.002_bib80","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1111\/j.1742-1241.2006.01109.x","article-title":"Transdermal buprenorphine in pain management\u2014experiences from clinical practice: Five case studies","volume":"60","author":"Louis","year":"2006","journal-title":"Int J Clin Pract"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib81","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1742-1241.2007.01531.x","article-title":"Challenging the equipotency calculation for transdermal buprenorphine: four case studies","volume":"62","author":"Likar","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib82","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1529-8027.2008.00194.x","article-title":"Short- and intermediate-term efficacy of buprenorphine TDS in chronic painful neuropathies","volume":"13","author":"Penza","year":"2008","journal-title":"J Peripher Nerv Syst"},{"issue":"2-3","key":"10.1016\/j.suponc.2012.05.002_bib83","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/S0304-3959(97)00172-3","article-title":"Dose-response relationship of opioids in nociceptive and neuropathic postoperative pain","volume":"74","author":"Benedetti","year":"1998","journal-title":"Pain"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib84","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1742-7843.2010.00649.x","article-title":"Pharmacokinetic\/pharmacodynamic relationships of transdermal buprenorphine and fentanyl in experimental human pain models","volume":"108","author":"Andresen","year":"2011","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"1-3","key":"10.1016\/j.suponc.2012.05.002_bib85","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.pain.2006.06.028","article-title":"Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine","volume":"126","author":"Koltzenburg","year":"2006","journal-title":"Pain"},{"issue":"18","key":"10.1016\/j.suponc.2012.05.002_bib86","doi-asserted-by":"crossref","first-page":"7074","DOI":"10.1523\/JNEUROSCI.20-18-07074.2000","article-title":"Dynorphin promotes abnormal pain and spinal opioid antinociceptive tolerance","volume":"20","author":"Vanderah","year":"2000","journal-title":"J Neurosci"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib87","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0014-2999(92)90355-8","article-title":"Effects of systemic morphine on diffuse noxious inhibitory controls: role of the periaqueductal grey","volume":"216","author":"Bouhassira","year":"1992","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib88","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0376-8716(00)00200-3","article-title":"Pain intolerance in opioid-maintained former opiate addicts: effect of long-acting maintenance agent","volume":"63","author":"Compton","year":"2001","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.suponc.2012.05.002_bib89","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/1756-9966-28-61","article-title":"Opioids switching with transdermal systems in chronic cancer pain","volume":"28","author":"Aurilio","year":"2009","journal-title":"J Exp Clin Cancer Res"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib90","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1007\/s005400170004","article-title":"Tolerance to the analgesic effect of buprenorphine, butorphanol, nalbuphine, and cyclorphan, and cross-tolerance to morphine","volume":"15","author":"Gringauz","year":"2001","journal-title":"J Anesth"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib91","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00000539-200107000-00039","article-title":"The antinociceptive effect of the combination of spinal morphine with systemic morphine or buprenorphine","volume":"93","author":"Nemirovsky","year":"2001","journal-title":"Anesth Analg"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib92","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1213\/00000539-199809000-00016","article-title":"Antinociceptive effect induced by the combined administration of spinal morphine and systemic buprenorphine","volume":"87","author":"Niv","year":"1998","journal-title":"Anesth Analg"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib93","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jpainsymman.2006.01.013","article-title":"Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine","volume":"32","author":"Mercadante","year":"2006","journal-title":"J Pain Symptom Manage"},{"issue":"22","key":"10.1016\/j.suponc.2012.05.002_bib94","doi-asserted-by":"crossref","first-page":"221801","DOI":"10.1103\/PhysRevLett.99.221801","article-title":"Observation of the decay B+\u2192 K+K\u2212pi+","volume":"99","author":"Aubert","year":"2007","journal-title":"Phys Rev Lett"},{"issue":"133","key":"10.1016\/j.suponc.2012.05.002_bib95","first-page":"3","article-title":"Buprenorphine: new pharmacological aspects","author":"Cowan","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib96","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1016\/j.ejpain.2005.02.002","article-title":"Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice","volume":"9","author":"K\u00f6gel","year":"2005","journal-title":"Eur J Pain"},{"issue":"11","key":"10.1016\/j.suponc.2012.05.002_bib97","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","article-title":"Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers","volume":"28","author":"Greenwald","year":"2003","journal-title":"Neuropsychopharmacology"},{"issue":"19","key":"10.1016\/j.suponc.2012.05.002_bib98","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2165\/00003495-200363190-00003","article-title":"Transdermal buprenorphine","volume":"63","author":"Evans","year":"2003","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib99","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.clinthera.2006.06.012","article-title":"Long-term management of chronic pain with transdermal buprenorphine: a multicenter, open-label, follow-up study in patients from three short-term clinical trials","volume":"28","author":"Likar","year":"2006","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib100","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1185\/03007998609110446","article-title":"An open study of sub-lingual buprenorphine in the treatment of chronic pain in the elderly","volume":"10","author":"Nasar","year":"1986","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"10.1016\/j.suponc.2012.05.002_bib101","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.ejpain.2008.09.005","article-title":"Gastrointestinal symptoms under opioid therapy: a prospective comparison of oral sustained-release hydromorphone, transdermal fentanyl, and transdermal buprenorphine","volume":"13","author":"Wirz","year":"2009","journal-title":"Eur J Pain"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib102","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1089\/jpm.2007.0200","article-title":"Adverse effects of transdermal opiates treating moderate-severe cancer pain in comparison to long-acting morphine: a meta-analysis and systematic review of the literature","volume":"11","author":"Tassinari","year":"2008","journal-title":"J Palliat Med"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib103","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1136\/gut.27.5.567","article-title":"Effect of modern analgesic drugs (tramadol, pentazocine, and buprenorphine) on the bile duct sphincter in man","volume":"27","author":"Staritz","year":"1986","journal-title":"Gut"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib104","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/BF00609196","article-title":"Effects of buprenorphine on motor activity of the sphincter of Oddi in man","volume":"36","author":"Cuer","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib105","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1097\/ALN.0b013e3181c38c25","article-title":"Incidence, reversal, and prevention of opioid-induced respiratory depression","volume":"112","author":"Dahan","year":"2010","journal-title":"Anesthesiology"},{"issue":"9","key":"10.1016\/j.suponc.2012.05.002_bib106","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1111\/j.1365-2044.1981.tb08867.x","article-title":"High dose buprenorphine for postoperative analgesia","volume":"36","author":"Budd","year":"1981","journal-title":"Anaesthesia"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib107","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1093\/bja\/ael051","article-title":"Buprenorphine induces ceiling in respiratory depression but not in analgesia","volume":"96","author":"Dahan","year":"2006","journal-title":"Br J Anaesth"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib108","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/bja\/aei145","article-title":"Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats","volume":"94","author":"Dahan","year":"2005","journal-title":"Br J Anaesth"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2012.05.002_bib109","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1191\/0269216306pm1126oa","article-title":"Opioid-induced respiratory effects: new data on buprenorphine","volume":"20","author":"Dahan","year":"2006","journal-title":"Palliat Med"},{"issue":"2-3","key":"10.1016\/j.suponc.2012.05.002_bib110","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.toxlet.2009.09.017","article-title":"Characteristics and comparative severity of respiratory response to toxic doses of fentanyl, methadone, morphine, and buprenorphine in rats","volume":"191","author":"Chevillard","year":"2009","journal-title":"Toxicol Lett"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib111","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.taap.2005.08.002","article-title":"Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation","volume":"212","author":"M\u00e9garbane","year":"2006","journal-title":"Toxicol Appl Pharmacol"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib112","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11095-007-9440-z","article-title":"Pharmacokinetic-pharmacodynamic modeling of the effectiveness and safety of buprenorphine and fentanyl in rats","volume":"25","author":"Yassen","year":"2008","journal-title":"Pharm Res"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib113","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00139709-200625020-00002","article-title":"Does high-dose buprenorphine cause respiratory depression?: possible mechanisms and therapeutic consequences","volume":"25","author":"M\u00e9garbane","year":"2006","journal-title":"Toxicol Rev"},{"issue":"1-3","key":"10.1016\/j.suponc.2012.05.002_bib114","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.1016\/j.forsciint.2010.09.014","article-title":"Fatalities in relation to buprenorphine snorting and ethanol co-ingestion: mechanisms of toxicity","volume":"207","author":"M\u00e9garbane","year":"2011","journal-title":"Forensic Sci Int"},{"issue":"9","key":"10.1016\/j.suponc.2012.05.002_bib115","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1046\/j.1360-0443.1998.93913859.x","article-title":"Six deaths linked to concomitant use of buprenorphine and benzodiazepines","volume":"93","author":"Reynaud","year":"1998","journal-title":"Addiction"},{"issue":"12","key":"10.1016\/j.suponc.2012.05.002_bib116","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1007\/s00228-004-0856-7","article-title":"Effect of benzodiazepines on the metabolism of buprenorphine in human liver microsomes","volume":"60","author":"Chang","year":"2005","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib117","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.drugalcdep.2005.01.004","article-title":"The effect of buprenorphine and benzodiazepines on respiration in the rat","volume":"79","author":"Nielsen","year":"2005","journal-title":"Drug Alcohol Depend"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib118","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/j.1360-0443.2006.01731.x","article-title":"Concurrent buprenorphine and benzodiazepines use and self-reported opioid toxicity in opioid substitution treatment","volume":"102","author":"Nielsen","year":"2007","journal-title":"Addiction"},{"issue":"suppl 2","key":"10.1016\/j.suponc.2012.05.002_bib119","doi-asserted-by":"crossref","first-page":"S79","DOI":"10.1016\/S0376-8716(03)00061-9","article-title":"Safety and health policy considerations related to the use of buprenorphine\/naloxone as an office-based treatment for opiate dependence","volume":"70","author":"Bridge","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"suppl 2","key":"10.1016\/j.suponc.2012.05.002_bib120","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","article-title":"Pharmacokinetics of the combination tablet of buprenorphine and naloxone","volume":"70","author":"Chiang","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"1-2","key":"10.1016\/j.suponc.2012.05.002_bib121","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0379-0738(01)00454-6","article-title":"Deaths involving buprenorphine: a compendium of French cases","volume":"121","author":"Kintz","year":"2001","journal-title":"Forensic Sci Int"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib122","first-page":"166","article-title":"Severe opiate withdrawal in a heroin user precipitated by a massive buprenorphine dose","volume":"176","author":"Clark","year":"2002","journal-title":"Med J Aust"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib123","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/clpt.1994.71","article-title":"Clinical pharmacology of buprenorphine: ceiling effects at high doses","volume":"55","author":"Walsh","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib124","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S0022-3565(25)10510-7","article-title":"Acute administration of buprenorphine in humans: partial agonist and blockade effects","volume":"274","author":"Walsh","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"issue":"1-3","key":"10.1016\/j.suponc.2012.05.002_bib125","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.drugalcdep.2011.10.022","article-title":"Road traffic crashes and prescribed methadone and buprenorphine: A French registry-based case-control study","volume":"123","author":"Corsenac","year":"2012","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib126","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0885-3924(99)00158-X","article-title":"Effects of opioids on driving ability","volume":"19","author":"Galski","year":"2000","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib127","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/s004820050091","article-title":"Opioids and driving ability [in German]","volume":"11","author":"Strumpf","year":"1997","journal-title":"Schmerz"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib128","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.drugalcdep.2003.08.002","article-title":"The effects of the opioid pharmacotherapies methadone, LAAM and buprenorphine, alone and in combination with alcohol, on simulated driving","volume":"72","author":"Lenn\u00e9","year":"2003","journal-title":"Drug Alcohol Depend"},{"key":"10.1016\/j.suponc.2012.05.002_bib129","first-page":"799","article-title":"Benzodiazepine use and motor vehicle accidents","volume":"44","author":"Thomas","year":"1998","journal-title":"Can Fam Physician"},{"issue":"2-3","key":"10.1016\/j.suponc.2012.05.002_bib130","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.forsciint.2005.04.011","article-title":"Driving impairment on buprenorphine and slow-release oral morphine in drug-dependent patients","volume":"152","author":"Giacomuzzi","year":"2005","journal-title":"Forensic Sci Int"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib131","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1097\/01.jcp.0000178417.60426.60","article-title":"Less impairment on one portion of a driving-relevant psychomotor battery in buprenorphine-maintained than in methadone-maintained patients: results of a randomized clinical trial","volume":"25","author":"Soyka","year":"2005","journal-title":"J Clin Psychopharmacol"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib132","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1159\/000101548","article-title":"Influence of peak and trough levels of opioid maintenance therapy on driving aptitude","volume":"13","author":"Baewert","year":"2007","journal-title":"Eur Addict Res"},{"issue":"suppl 2","key":"10.1016\/j.suponc.2012.05.002_bib133","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1055\/s-2008-1081067","article-title":"Driving ability under opioids: current assessment of published studies [in German]","volume":"133","author":"Sabatowski","year":"2008","journal-title":"Dtsch Med Wochenschr"},{"issue":"2-3","key":"10.1016\/j.suponc.2012.05.002_bib134","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.drugalcdep.2011.01.017","article-title":"The impact of long-term maintenance treatment with buprenorphine on complex psychomotor and cognitive function","volume":"117","author":"Shmygalev","year":"2011","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib135","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1213\/01.ane.0000281078.65585.1e","article-title":"Assessing cognitive and psychomotor performance under long-term treatment with transdermal buprenorphine in chronic noncancer pain patients","volume":"105","author":"Dagtekin","year":"2007","journal-title":"Anesth Analg"},{"issue":"133","key":"10.1016\/j.suponc.2012.05.002_bib136","first-page":"19","article-title":"Buprenorphine TDS: use in daily practice, benefits for patients","author":"Radbruch","year":"2003","journal-title":"Int J Clin Pract Suppl"},{"key":"10.1016\/j.suponc.2012.05.002_bib137","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/978-1-4615-5347-2_5","article-title":"Centrally-mediated opioid-induced immunosuppression","volume":"437","author":"Brinkman","year":"1998","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib138","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1097\/01.mjt.0000132250.95650.85","article-title":"Opioid therapy and immunosuppression: a review","volume":"11","author":"Vallejo","year":"2004","journal-title":"Am J Ther"},{"issue":"10","key":"10.1016\/j.suponc.2012.05.002_bib139","doi-asserted-by":"crossref","first-page":"7164","DOI":"10.1074\/jbc.M604367200","article-title":"Transcriptional and epigenetic regulation of interleukin-2 gene in activated T cells by morphine","volume":"282","author":"Wang","year":"2007","journal-title":"J Biol Chem"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2012.05.002_bib140","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1191\/0269216306pm1124oa","article-title":"Opioids and the immune system","volume":"20","author":"Sacerdote","year":"2006","journal-title":"Palliat Med"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib141","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/SPC.0b013e3282f5272e","article-title":"Opioid-induced immunosuppression","volume":"2","author":"Sacerdote","year":"2008","journal-title":"Curr Opin Support Palliat Care"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib142","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1159\/000078444","article-title":"Effects of fentanyl on natural killer cell activity and on resistance to tumor metastasis in rats","volume":"11","author":"Shavit","year":"2004","journal-title":"Neuroimmunomodulation"},{"issue":"7","key":"10.1016\/j.suponc.2012.05.002_bib143","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.biopha.2006.06.015","article-title":"Pain management: is opioid immunosuppression a clinical problem?","volume":"60","author":"Budd","year":"2006","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"10.1016\/j.suponc.2012.05.002_bib144","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0006-2952(03)00085-6","article-title":"Opioid-induced immunosuppression: is it centrally mediated or peripherally mediated?","volume":"65","author":"Wei","year":"2003","journal-title":"Biochem Pharmacol"},{"issue":"11","key":"10.1016\/j.suponc.2012.05.002_bib145","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.1073\/pnas.95.11.6326","article-title":"Abolition of morphine-immunosuppression in mice lacking the mu-opioid receptor gene","volume":"95","author":"Gav\u00e9riaux-Ruff","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib146","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/S0022-3565(25)12916-9","article-title":"Evidence for sympathetic and adrenal involvement in the immunomodulatory effects of acute morphine treatment in rats","volume":"277","author":"Fecho","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib147","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1016\/j.bbi.2007.01.001","article-title":"Buprenorphine ameliorates the effect of surgery on hypothalamus-pituitary-adrenal axis, natural killer cell activity, and metastatic colonization in rats in comparison with morphine or fentanyl treatment","volume":"21","author":"Franchi","year":"2007","journal-title":"Brain Behav Immun"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib148","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0162-3109(00)00198-3","article-title":"Differential effects of buprenorphine and morphine on immune and neuroendocrine functions following acute administration in the rat mesencephalon periaqueductal gray","volume":"48","author":"Gomez-Flores","year":"2000","journal-title":"Immunopharmacology"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib149","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1016\/S0022-3565(25)22517-4","article-title":"A mechanism of action for morphine-induced immunosuppression: corticosterone mediates morphine-induced suppression of natural killer cell activity","volume":"270","author":"Freier","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib150","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1189\/jlb.72.1.43","article-title":"Differential morphine tolerance development in the modulation of macrophage cytokine production in mice","volume":"72","author":"Limiroli","year":"2002","journal-title":"J Leukoc Biol"},{"issue":"1-2","key":"10.1016\/j.suponc.2012.05.002_bib151","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.pain.2004.04.020","article-title":"Chronic fentanyl or buprenorphine infusion in the mouse: similar analgesic profile but different effects on immune responses","volume":"110","author":"Martucci","year":"2004","journal-title":"Pain"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib152","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/S0022-3565(25)12317-3","article-title":"Assessment of the involvement of central nervous system and peripheral opioid receptors in the immunomodulatory effects of acute morphine treatment in rats","volume":"276","author":"Fecho","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"issue":"11","key":"10.1016\/j.suponc.2012.05.002_bib153","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1001\/archsurg.1987.01400230050009","article-title":"The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer","volume":"122","author":"Tartter","year":"1987","journal-title":"Arch Surg"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib154","first-page":"190","article-title":"Preoperative natural killer cell activity: correlation with distant metastases in curatively research colorectal carcinomas","volume":"82","author":"Koda","year":"1997","journal-title":"Int Surg"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib155","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1200\/JCO.1987.5.3.348","article-title":"Correlation of stress factors with sustained depression of natural killer cell activity and predicted prognosis in patients with breast cancer","volume":"5","author":"Levy","year":"1987","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib156","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0002-9610(89)90134-7","article-title":"Natural killer cells and metastases from pharyngeal carcinoma","volume":"158","author":"Schantz","year":"1989","journal-title":"Am J Surg"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib157","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/(SICI)1097-0142(19970201)79:3<474::AID-CNCR8>3.0.CO;2-I","article-title":"Autologous tumor killing activity as a prognostic factor in primary resected non\u2013small cell carcinoma of the lung","volume":"79","author":"Fujisawa","year":"1997","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib158","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1159\/000217850","article-title":"Expansion of peripheral blood natural killer cells correlates with clinical outcome in cancer patients receiving recombinant subcutaneous interleukin-2 and interferon-alpha-2","volume":"14","author":"Atzpodien","year":"1993","journal-title":"Tumour Biol"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib159","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0304-3959(93)90095-7","article-title":"Morphine attenuates surgery-induced enhancement of metastatic colonization in rats","volume":"54","author":"Page","year":"1993","journal-title":"Pain"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib160","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1006\/brbi.1994.1022","article-title":"The role of LGL\/NK cells in surgery-induced promotion of metastasis and its attenuation by morphine","volume":"8","author":"Page","year":"1994","journal-title":"Brain Behav Immun"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib161","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1093\/bja\/81.2.216","article-title":"Preoperative versus postoperative administration of morphine: impact on the neuroendocrine, behavioural, and metastatic-enhancing effects of surgery","volume":"81","author":"Page","year":"1998","journal-title":"Br J Anaesth"},{"issue":"1-2","key":"10.1016\/j.suponc.2012.05.002_bib162","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S0304-3959(00)00403-6","article-title":"Evidence that postoperative pain is a mediator of the tumor-promoting effects of surgery in rats","volume":"90","author":"Page","year":"2001","journal-title":"Pain"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib163","first-page":"43","article-title":"Stress and morphine affect survival of rats challenged with a mammary ascites tumor (MAT 13762B)","volume":"3","author":"Lewis","year":"1983","journal-title":"Nat Immun Cell Growth Regul"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib164","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1097\/00044067-200507000-00004","article-title":"Surgery-induced immunosuppression and postoperative pain management","volume":"16","author":"Page","year":"2005","journal-title":"AACN Clin Issues"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib165","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/00000542-200610000-00008","article-title":"Can anesthetic technique for primary breast cancer surgery affect recurrence or metastasis?","volume":"105","author":"Exadaktylos","year":"2006","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib166","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/ALN.0b013e31817f5b73","article-title":"Anesthetic technique for radical prostatectomy surgery affects cancer recurrence: a retrospective analysis","volume":"109","author":"Biki","year":"2008","journal-title":"Anesthesiology"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib167","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S1521-6616(03)00177-3","article-title":"No detrimental effect from chronic exposure to buprenorphine on corticosteroid-binding globulin and corticosensitive immune parameters","volume":"109","author":"D'Elia","year":"2003","journal-title":"Clin Immunol"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib168","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.bbi.2007.12.013","article-title":"Buprenorphine and methadone maintenance treatment of heroin addicts preserves immune function","volume":"22","author":"Sacerdote","year":"2008","journal-title":"Brain Behav Immun"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib169","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s00213-005-2239-x","article-title":"Randomized clinical trial to compare the effects of methadone and buprenorphine on the immune system in drug abusers","volume":"179","author":"Neri","year":"2005","journal-title":"Psychopharmacology (Berl)"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib170","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s00101-003-0506-y","article-title":"Opioids and immunosuppression","volume":"52","author":"Welters","year":"2003","journal-title":"Anaesthesist"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib171","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/0885-3924(94)90166-X","article-title":"Altered sexual function and decreased testosterone in patients receiving intraspinal opioids","volume":"9","author":"Paice","year":"1994","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib172","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.bone.2011.11.014","article-title":"Factors associated with screening or treatment initiation among male United States veterans at risk for osteoporosis fracture","volume":"50","author":"Nelson","year":"2012","journal-title":"Bone"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib173","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.neuroscience.2006.02.044","article-title":"Single opioid administration modifies gonadal steroids in both the CNS and plasma of male rats","volume":"140","author":"Ceccarelli","year":"2006","journal-title":"Neuroscience"},{"issue":"7","key":"10.1016\/j.suponc.2012.05.002_bib174","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1016\/j.psyneuen.2010.12.017","article-title":"Chronic pain therapy and hypothalamic-pituitary-adrenal axis impairment","volume":"36","author":"Aloisi","year":"2011","journal-title":"Psychoneuroendocrinology"},{"key":"10.1016\/j.suponc.2012.05.002_bib175","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/1477-7827-9-26","article-title":"Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients","volume":"9","author":"Aloisi","year":"2011","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib176","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/jc.2004-0929","article-title":"Plasma testosterone and sexual function in men receiving buprenorphine maintenance for opioid dependence","volume":"90","author":"Bliesener","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib177","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/j.1365-2605.2007.00824.x","article-title":"Hypogonadism in men receiving methadone and buprenorphine maintenance treatment","volume":"32","author":"Hallinan","year":"2009","journal-title":"Int J Androl"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib178","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/j.1743-6109.2007.00702.x","article-title":"Erectile dysfunction in men receiving methadone and buprenorphine maintenance treatment","volume":"5","author":"Hallinan","year":"2008","journal-title":"J Sex Med"},{"issue":"12","key":"10.1016\/j.suponc.2012.05.002_bib179","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1507\/endocrj.EJ11-0095","article-title":"Endocrine and behavioural effects of transdermal buprenorphine in pain-suffering women of different reproductive ages","volume":"58","author":"Aurilio","year":"2011","journal-title":"Endocr J"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib180","doi-asserted-by":"crossref","first-page":"387","DOI":"10.7326\/0003-4819-150-6-200903170-00103","article-title":"QTc interval screening in methadone treatment","volume":"150","author":"Krantz","year":"2009","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib181","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1111\/j.1360-0443.2009.02549.x","article-title":"Prevalence and clinical relevance of corrected QT interval prolongation during methadone and buprenorphine treatment: a mortality assessment study","volume":"104","author":"Anchersen","year":"2009","journal-title":"Addiction"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib182","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1080\/10550880802122596","article-title":"Electrocardiogram characteristics of methadone and buprenorphine maintained subjects","volume":"27","author":"Athanasos","year":"2008","journal-title":"J Addict Dis"},{"issue":"22","key":"10.1016\/j.suponc.2012.05.002_bib183","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1001\/archinte.167.22.2469","article-title":"QT-interval effects of methadone, levomethadyl, and buprenorphine in a randomized trial","volume":"167","author":"Wedam","year":"2007","journal-title":"Arch Intern Med"},{"issue":"1-2","key":"10.1016\/j.suponc.2012.05.002_bib184","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drugalcdep.2009.03.020","article-title":"Comparing overdose mortality associated with methadone and buprenorphine treatment","volume":"104","author":"Bell","year":"2009","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib185","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/0304-3959(84)90824-8","article-title":"The prevalence of pain complaints in a general population","volume":"18","author":"Crook","year":"1984","journal-title":"Pain"},{"issue":"22","key":"10.1016\/j.suponc.2012.05.002_bib186","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1001\/archinternmed.2010.442","article-title":"Analgesic use in the elderly: the \u201cpain\u201d and simple truth: comment on \u201cThe comparative safety of analgesics in older adults with arthritis\u201d","volume":"170","author":"Graf","year":"2010","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib187","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0197-4572(86)80069-6","article-title":"Narcotic analgesics for chronic pain","volume":"7","author":"Todd","year":"1986","journal-title":"Geriatr Nurs"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib188","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0749-0690(18)30622-0","article-title":"Use of analgesics in the elderly","volume":"6","author":"Wall","year":"1990","journal-title":"Clin Geriatr Med"},{"issue":"22","key":"10.1016\/j.suponc.2012.05.002_bib189","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1001\/archinte.163.22.2716","article-title":"Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts","volume":"163","author":"Fick","year":"2003","journal-title":"Arch Intern Med"},{"issue":"6","key":"10.1016\/j.suponc.2012.05.002_bib190","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1157\/13098717","article-title":"Effectiveness and safety of transdermal buprenorphine for chronic pain treatment in the elderly: a prospective observational study [in Spanish]","volume":"128","author":"Muriel Villoria","year":"2007","journal-title":"Med Clin (Barc)"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib191","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1093\/bja\/64.3.276","article-title":"Buprenorphine disposition in patients with renal impairment: single and continuous dosing, with special reference to metabolites","volume":"64","author":"Hand","year":"1990","journal-title":"Br J Anaesth"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib192","first-page":"257","article-title":"Inhibition of methadone and buprenorphine N-dealkylations by three HIV-1 protease inhibitors","volume":"26","author":"Iribarne","year":"1998","journal-title":"Drug Metab Dispos"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib193","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.arr.2010.06.001","article-title":"Pharmacogenetics of cytochrome P450 (CYP) in the elderly","volume":"9","author":"Seripa","year":"2010","journal-title":"Ageing Res Rev"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib194","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/S0090-9556(25)06808-4","article-title":"Glucuronidation in vitro and in vivo","volume":"15","author":"Mistry","year":"1987","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib195","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/j.1365-2796.2006.01667.x","article-title":"Fracture risk associated with the use of morphine and opiates","volume":"260","author":"Vestergaard","year":"2006","journal-title":"J Intern Med"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2012.05.002_bib196","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1191\/0269216306pm1127oa","article-title":"Renal impairment: a challenge for opioid treatment?","volume":"20","author":"B\u00f6ger","year":"2006","journal-title":"Palliat Med"},{"issue":"8","key":"10.1016\/j.suponc.2012.05.002_bib197","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ejpain.2005.12.001","article-title":"Effects of intermittent hemodialysis on buprenorphine and norbuprenorphine plasma concentrations in chronic pain patients treated with transdermal buprenorphine","volume":"10","author":"Filitz","year":"2006","journal-title":"Eur J Pain"},{"issue":"1","key":"10.1016\/j.suponc.2012.05.002_bib198","first-page":"115","article-title":"Transdermal buprenorphine in the management of persistent pain\u2014safety aspects","volume":"2","author":"Likar","year":"2006","journal-title":"Ther Clin Risk Manag"},{"issue":"8","key":"10.1016\/j.suponc.2012.05.002_bib199","doi-asserted-by":"crossref","first-page":"2835","DOI":"10.1523\/JNEUROSCI.5412-10.2011","article-title":"Neural correlates of an injury-free model of central sensitization induced by opioid withdrawal in humans","volume":"31","author":"Wanigasekera","year":"2011","journal-title":"J Neurosci"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib200","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1001\/archpsyc.1978.01770280111012","article-title":"Human pharmacology and abuse potential of the analgesic buprenorphine: a potential agent for treating narcotic addiction","volume":"35","author":"Jasinski","year":"1978","journal-title":"Arch Gen Psychiatry"},{"issue":"suppl 2","key":"10.1016\/j.suponc.2012.05.002_bib201","doi-asserted-by":"crossref","first-page":"S13","DOI":"10.1016\/S0376-8716(03)00056-5","article-title":"The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic","volume":"70","author":"Walsh","year":"2003","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib202","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1007\/BF02246290","article-title":"Effects of buprenorphine and methadone in methadone-maintained subjects","volume":"119","author":"Walsh","year":"1995","journal-title":"Psychopharmacology (Berl)"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib203","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1111\/j.1527-3458.2002.tb00235.x","article-title":"Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction","volume":"8","author":"Robinson","year":"2002","journal-title":"CNS Drug Rev"},{"issue":"2-3","key":"10.1016\/j.suponc.2012.05.002_bib204","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.drugalcdep.2007.04.006","article-title":"Sublingual buprenorphine\/naloxone precipitated withdrawal in subjects maintained on 100mg of daily methadone","volume":"90","author":"Rosado","year":"2007","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib205","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1007\/s002130000637","article-title":"Effects of buprenorphine\/naloxone in opioid-dependent humans","volume":"154","author":"Stoller","year":"2001","journal-title":"Psychopharmacology (Berl)"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib206","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/clpt.1989.147","article-title":"Use of buprenorphine in the treatment of opiate addiction","volume":"46","author":"Johnson","year":"1989","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.suponc.2012.05.002_bib207","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.1989.66","article-title":"Sublingual versus subcutaneous buprenorphine in opiate abusers","volume":"45","author":"Jasinski","year":"1989","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib208","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0022-3565(25)11174-9","article-title":"Acute effects of buprenorphine, hydromorphone and naloxone in methadone-maintained volunteers","volume":"261","author":"Strain","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib209","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S0376-8716(00)00141-1","article-title":"Thrice-weekly supervised dosing with the combination buprenorphine-naloxone tablet is preferred to daily supervised dosing by opioid-dependent humans","volume":"61","author":"Amass","year":"2001","journal-title":"Drug Alcohol Depend"},{"issue":"suppl 1","key":"10.1016\/j.suponc.2012.05.002_bib210","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1159\/000052035","article-title":"Substitution with buprenorphine in methadone- and morphine sulfate-dependent patients","volume":"4","author":"Bouchez","year":"1998","journal-title":"Eur Addict Res"},{"issue":"9358","key":"10.1016\/j.suponc.2012.05.002_bib211","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1016\/S0140-6736(03)12612-8","article-title":"Maintenance buprenorphine for opioid users","volume":"361","author":"Law","year":"2003","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib212","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1521-0391.1997.tb00559.x","article-title":"A protocol to switch high-dose, methadone-maintained subjects to buprenorphine","volume":"6","author":"Levin","year":"1997","journal-title":"Am J Addict"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib213","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1151\/spp04224","article-title":"Practical considerations for the clinical use of buprenorphine","volume":"2","author":"Jones","year":"2004","journal-title":"Sci Pract Perspect"},{"issue":"2","key":"10.1016\/j.suponc.2012.05.002_bib214","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/105500490290087901","article-title":"The use of intravenous buprenorphine for the treatment of opioid withdrawal in medically ill hospitalized patients","volume":"11","author":"Welsh","year":"2002","journal-title":"Am J Addict"},{"issue":"4","key":"10.1016\/j.suponc.2012.05.002_bib215","article-title":"Buprenorphine for the management of opioid withdrawal","author":"Gowing","year":"2004","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"10.1016\/j.suponc.2012.05.002_bib216","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1185\/03007995.2011.586332","article-title":"Can morphine still be considered to be the standard for treating chronic pain?","volume":"27","author":"Bekkering","year":"2011","journal-title":"Curr Med Res Opin"},{"issue":"3","key":"10.1016\/j.suponc.2012.05.002_bib217","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1007\/s10198-008-0134-1","article-title":"Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach","volume":"10","author":"Hass","year":"2009","journal-title":"Eur J Health Econ"}],"container-title":["The Journal of Supportive Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544679412000882?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544679412000882?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T12:51:31Z","timestamp":1743771091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544679412000882"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,11]]},"references-count":217,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012,11]]}},"alternative-id":["S1544679412000882"],"URL":"https:\/\/doi.org\/10.1016\/j.suponc.2012.05.002","relation":{},"ISSN":["1544-6794"],"issn-type":[{"value":"1544-6794","type":"print"}],"subject":[],"published":{"date-parts":[[2012,11]]}}}